| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/15/2023 | 52.14% | HC Wainwright & Co. | → $59 | Reiterates | Buy → Buy |
| 11/07/2023 | 46.98% | Benchmark | → $57 | Reiterates | Buy → Buy |
| 11/06/2023 | 52.14% | HC Wainwright & Co. | $55 → $59 | Maintains | Buy |
| 08/10/2023 | 41.83% | HC Wainwright & Co. | → $55 | Reiterates | Buy → Buy |
| 07/28/2023 | 10.88% | Cantor Fitzgerald | → $43 | Initiates Coverage On | → Overweight |
| 07/26/2023 | -35.53% | SVB Leerink | → $25 | Initiates Coverage On | → Outperform |
| 07/25/2023 | 46.98% | Benchmark | → $57 | Reiterates | Buy → Buy |
| 07/25/2023 | 41.83% | HC Wainwright & Co. | → $55 | Reiterates | Buy → Buy |
| 06/20/2023 | 46.98% | Benchmark | → $57 | Reiterates | Buy → Buy |
| 06/05/2023 | 41.83% | HC Wainwright & Co. | $58 → $55 | Reiterates | → Buy |
| 04/04/2023 | 46.98% | Benchmark | → $57 | Reiterates | → Buy |
| 04/04/2023 | 49.56% | HC Wainwright & Co. | → $58 | Reiterates | → Buy |
| 02/22/2023 | 49.56% | HC Wainwright & Co. | → $58 | Reiterates | → Buy |
| 02/21/2023 | 49.56% | HC Wainwright & Co. | → $58 | Reiterates | → Buy |
| 08/01/2022 | 49.56% | HC Wainwright & Co. | → $58 | Initiates Coverage On | → Buy |
| 07/01/2022 | 46.98% | Benchmark | → $57 | Initiates Coverage On | → Buy |
What is the target price for Belite Bio (BLTE)?
The latest price target for Belite Bio (NASDAQ: BLTE) was reported by HC Wainwright & Co. on November 15, 2023. The analyst firm set a price target for $59.00 expecting BLTE to rise to within 12 months (a possible 52.14% upside). 14 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Belite Bio (BLTE)?
The latest analyst rating for Belite Bio (NASDAQ: BLTE) was provided by HC Wainwright & Co., and Belite Bio reiterated their buy rating.
When is the next analyst rating going to be posted or updated for Belite Bio (BLTE)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Belite Bio, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Belite Bio was filed on November 15, 2023 so you should expect the next rating to be made available sometime around November 15, 2024.
Is the Analyst Rating Belite Bio (BLTE) correct?
While ratings are subjective and will change, the latest Belite Bio (BLTE) rating was a reiterated with a price target of $0.00 to $59.00. The current price Belite Bio (BLTE) is trading at is $38.78, which is within the analyst's predicted range.